This article was reprinted from kaiserhealthnews.

This article was reprinted from with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an editorially independent information service, is a program of the Kaiser Family members Foundation, a nonpartisan healthcare policy research business unaffiliated with Kaiser Permanente.. Activists protest Novartis problem to Indian patent law In this guest post in the Center for Global Health Policy’s ‘Science Speaks’ blog, Brook Baker of the Northeastern University College of Law System on Human Rights and the Global Overall economy, ‘describe[s] and comment[s] on pharmaceutical firm Novartis’s court concern to India’s strict requirements of patenting medicine’ and world-wide protests against the company that took place last week prior to its shareholder getting together with .Studies evaluating mutational profiles of major tumors and connected metastatic lesions16,17 or regional recurrences18 have provided evidence of intratumor heterogeneity at nucleotide resolution. Intratumor heterogeneity within main tumors and linked metastatic sites has not been systematically characterized by next-generation sequencing. We applied exome sequencing, chromosome aberration analysis, and DNA ploidy profiling to study multiple spatially separated biopsy samples from major renal-cell carcinomas and linked metastatic sites. We in-vestigated the phenotypic effects of genetic intratumor heterogeneity and the representation of the tumor genomic landscape by a single tumor-biopsy sample, the current basis for most biomarker discovery and personalized-medicine approaches.